This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Berry, D. A Search for Related Content PubMed PubMed Citation Articles by Berry, D. A Social Bookmarking                   What's this?

Introduction to Bayesian methods III: use and interpretation of Bayesian tools in design and analysis

Department of Biostatistics and Applied Mathematics, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd., Unit 447, Houston, TX 77030-4009, USA dberry{at}mdanderson.org

The Bayesian approach and several of its advantages in drug and medical device development are described. One advantage from the perspective of analysis is that it provides a methodology for synthesizing information. However, taking a Bayesian approach to designing clinical trials is potentially more valuable than using this approach in analyzing trial results. Bayesian methodology provides a mechanism for updating what is known as results accumulate during a trial. Such updating can be incorporated completely explicitly and prospectively. An important way in which the Bayesian approach can be used is in calculating the predictive probability distribution of future results on the basis of current results. I show how to exploit predictive distributions in adapting to results that accumulate during the course of a trial. Possible adaptations including decreasing or increasing sample size, dropping treatment arms, and modifying the randomization proportions to the various arms depending on the interim results. Consequences of taking a Bayesian approach to clinical trial design are efficiency, better treatment of patients in the trial, and greater precision regarding the primary endpoints. An example of the last of these is Bayesian modeling of the relationship between early and longer term endpoints. Such modeling also enables earlier decision making. Case studies 2 and 3 deal with trials that were shorter and smaller, respectively, because of such modeling.

Clinical Trials, Vol. 2, No. 4, 295-300 (2005)
DOI: 10.1191/1740774505cn100oa


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				S. Biswas, D. D Liu, J J. Lee, and D. A Berry Bayesian clinical trials at the University of Texas M. D. Anderson Cancer Center Clinical Trials, June 1, 2009; 6(3): 205 - 216. [Abstract] [PDF]

				J J. Lee Adaptive Designs for Efficacy and Toxicity Endpoints in Early Drug Development Am. Assoc. Cancer Res. Educ. Book, April 12, 2008; 2008(1): 631 - 636. [Abstract] [Full Text] [PDF]

				J J. Lee and D. D Liu A predictive probability design for phase II cancer clinical trials Clinical Trials, April 1, 2008; 5(2): 93 - 106. [Abstract] [PDF]